<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00645853</url>
  </required_header>
  <id_info>
    <org_study_id>D1250C00042</org_study_id>
    <nct_id>NCT00645853</nct_id>
  </id_info>
  <brief_title>Long-term Safety in Atrial Fibrillation Patients</brief_title>
  <official_title>Long-term Treatment With the Oral Direct Thrombin Inhibitor AZD0837, Compared to Vitamin-K Antagonists, as Stroke Prevention in Patients With Non-valvular Atrial Fibrillation and One or More Risk Factors for Stroke and Systemic Embolic Events. A 5-year Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide safety and tolerability data for AZD0837 during
      long-term treatment (5 years) in patients with non-valvular atrial fibrillation (AF) and one
      or more additional risk factors for stroke and systemic embolic events (moderate to high risk
      patients).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding: Number of Patients With Any Bleeding Event, During Treatment Period</measure>
    <time_frame>154-711 days on treatment</time_frame>
    <description>Participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alanine Transaminase (ALAT): Number of Patients With ALAT&gt;=3xULN, Post Baseline</measure>
    <time_frame>From baseline to Follow up</time_frame>
    <description>ULN=Upper limit of Normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin: Number of Patients With Bilirubin&gt;=2xULN, Post Baseline</measure>
    <time_frame>From baseline to Follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine: Absolute Change From Baseline, at End of Treatment</measure>
    <time_frame>Baseline and End of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer:Median and Quartile Range at End of Treatment</measure>
    <time_frame>End of treatment</time_frame>
    <description>Median (Lower Quartile-Upper Quartile ), ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated Partial Thromboplastin Time (APTT): Absolute Change From Baseline to End of Treatment</measure>
    <time_frame>Baseline and End of treatment</time_frame>
    <description>Median Full range, Seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroconvulsive Therapy (ECT): Absolute Change From Baseline to End of Treatment</measure>
    <time_frame>Baseline and End of Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AZD0837: Plasma Concentration of AZD0837 at End of Treatment</measure>
    <time_frame>End of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AR-H067637XX, the Active Major Metabolite of AD0837: Plasma Concentration of AR-H067637XX, at End of Treatment</measure>
    <time_frame>154-711 days on treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">523</enrollment>
  <condition>Persistent or Permanent Nonvalvular Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD0837</intervention_name>
    <description>Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VKA INR 2-3</intervention_name>
    <description>Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5</description>
    <arm_group_label>2</arm_group_label>
    <other_name>warfarin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with paroxysmal, persistent or permanent Non Valvular Atrial Fibrillation
             with one or more additional risk factors for stroke and systemic embolic event

          -  completing treatment with study drug in D1250C00008.

        Exclusion Criteria:

          -  Atrial Fibrillation secondary to reversible disorders, eg hyperthyroidism

          -  Presence of a valvular heart disease, mechanical heart valves, active endocarditis,
             left ventricular aneurysm or thrombus, atrial myxoma or any condition other than
             Atrial Fibrillation requiring chronic anticoagulation treatment

          -  Myocardial infarction, heart surgery or percutaneous coronary intervention (PCI)
             within the previous three months prior to inclusion; Stroke and/or systemic embolism
             within the previous 30 days prior to inclusion

          -  Conditions associated with increased risk of major bleeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Hvilstedt Rasmussen, MD, PhD, FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Cardiology at Heart Centre Aalborg Aarhus University Hospital DK 9100 Aalborg Denmark</affiliation>
  </overall_official>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2008</study_first_submitted>
  <study_first_submitted_qc>March 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2008</study_first_posted>
  <results_first_submitted>June 30, 2011</results_first_submitted>
  <results_first_submitted_qc>February 2, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 6, 2012</results_first_posted>
  <last_update_submitted>March 20, 2012</last_update_submitted>
  <last_update_submitted_qc>March 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study population included male and female participants &gt;18 years of age with chronic non-valvular Atrial Fibrillation. The participants were recruited during the time period from 25 October 2007 to 20 May 2008 at medical clinics in Europe.</recruitment_details>
      <pre_assignment_details>All participants had previously participated in the Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation (NCT00684307) study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD0837</title>
          <description>Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od.</description>
        </group>
        <group group_id="P2">
          <title>VKA, INR 2-3</title>
          <description>Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="288"/>
                <participants group_id="P2" count="235"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>No of Patients After Dose Switch</title>
              <participants_list>
                <participants group_id="P1" count="209">All patients in the AZD0837 arm switched from their initial doses, to a general dose of 300 mg od</participants>
                <participants group_id="P2" count="188">No changes for VKA patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued Patient No Due to Closure</title>
              <participants_list>
                <participants group_id="P1" count="196">No of patients discontinued due the study termination caused tablet formulation stability problems</participants>
                <participants group_id="P2" count="178">No of patients discontinued due the study termination caused tablet formulation stability problems</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>AZ Study Closure in Hungary</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="196"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AZ study closure in Hungary</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>recall of ICF, planned operation, death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD0837</title>
          <description>Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od.</description>
        </group>
        <group group_id="B2">
          <title>VKA, INR 2-3</title>
          <description>Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="288"/>
            <count group_id="B2" value="235"/>
            <count group_id="B3" value="523"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.9" lower_limit="34" upper_limit="93"/>
                    <measurement group_id="B2" value="68.0" lower_limit="33" upper_limit="86"/>
                    <measurement group_id="B3" value="68.95" lower_limit="33" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bleeding: Number of Patients With Any Bleeding Event, During Treatment Period</title>
        <description>Participants</description>
        <time_frame>154-711 days on treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0837</title>
            <description>Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od.</description>
          </group>
          <group group_id="O2">
            <title>VKA, INR 2-3</title>
            <description>Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding: Number of Patients With Any Bleeding Event, During Treatment Period</title>
          <description>Participants</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Transaminase (ALAT): Number of Patients With ALAT&gt;=3xULN, Post Baseline</title>
        <description>ULN=Upper limit of Normal</description>
        <time_frame>From baseline to Follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0837</title>
            <description>Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od.</description>
          </group>
          <group group_id="O2">
            <title>VKA, INR 2-3</title>
            <description>Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Transaminase (ALAT): Number of Patients With ALAT&gt;=3xULN, Post Baseline</title>
          <description>ULN=Upper limit of Normal</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bilirubin: Number of Patients With Bilirubin&gt;=2xULN, Post Baseline</title>
        <time_frame>From baseline to Follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0837</title>
            <description>Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od.</description>
          </group>
          <group group_id="O2">
            <title>VKA, INR 2-3</title>
            <description>Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5</description>
          </group>
        </group_list>
        <measure>
          <title>Bilirubin: Number of Patients With Bilirubin&gt;=2xULN, Post Baseline</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine: Absolute Change From Baseline, at End of Treatment</title>
        <time_frame>Baseline and End of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0837</title>
            <description>Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od.</description>
          </group>
          <group group_id="O2">
            <title>VKA, INR 2-3</title>
            <description>Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine: Absolute Change From Baseline, at End of Treatment</title>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" spread="-67.0" lower_limit="-67.0" upper_limit="120.0"/>
                    <measurement group_id="O2" value="-1.17" spread="-56.0" lower_limit="-56.0" upper_limit="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>D-dimer:Median and Quartile Range at End of Treatment</title>
        <description>Median (Lower Quartile-Upper Quartile ), ng/mL</description>
        <time_frame>End of treatment</time_frame>
        <population>Only patients who switched to one common dose, 300 mg od, are included in the AZD0837 analysis</population>
        <group_list>
          <group group_id="O1">
            <title>AZD0837</title>
            <description>Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od.</description>
          </group>
          <group group_id="O2">
            <title>VKA, INR 2-3</title>
            <description>Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5</description>
          </group>
        </group_list>
        <measure>
          <title>D-dimer:Median and Quartile Range at End of Treatment</title>
          <description>Median (Lower Quartile-Upper Quartile ), ng/mL</description>
          <population>Only patients who switched to one common dose, 300 mg od, are included in the AZD0837 analysis</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9" lower_limit="43.3" upper_limit="128.4"/>
                    <measurement group_id="O2" value="54.9" lower_limit="31.9" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Activated Partial Thromboplastin Time (APTT): Absolute Change From Baseline to End of Treatment</title>
        <description>Median Full range, Seconds</description>
        <time_frame>Baseline and End of treatment</time_frame>
        <population>Only patients who switched to one common dose, 300 mg od, are included in the AZD0837 analysis</population>
        <group_list>
          <group group_id="O1">
            <title>AZD0837</title>
            <description>Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od.</description>
          </group>
        </group_list>
        <measure>
          <title>Activated Partial Thromboplastin Time (APTT): Absolute Change From Baseline to End of Treatment</title>
          <description>Median Full range, Seconds</description>
          <population>Only patients who switched to one common dose, 300 mg od, are included in the AZD0837 analysis</population>
          <units>sec</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="-62" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Electroconvulsive Therapy (ECT): Absolute Change From Baseline to End of Treatment</title>
        <time_frame>Baseline and End of Treatment</time_frame>
        <population>Only patients who switched to one dose, 300 mg od, are included in the AZD0837 analysis</population>
        <group_list>
          <group group_id="O1">
            <title>AZD0837</title>
            <description>Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od.</description>
          </group>
        </group_list>
        <measure>
          <title>Electroconvulsive Therapy (ECT): Absolute Change From Baseline to End of Treatment</title>
          <population>Only patients who switched to one dose, 300 mg od, are included in the AZD0837 analysis</population>
          <units>sec</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0" lower_limit="-5" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AZD0837: Plasma Concentration of AZD0837 at End of Treatment</title>
        <time_frame>End of treatment</time_frame>
        <population>Only patients who switched to one dose, 300 mg od, are included in the AZD0837 analysis</population>
        <group_list>
          <group group_id="O1">
            <title>AZD0837</title>
            <description>Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od.</description>
          </group>
        </group_list>
        <measure>
          <title>AZD0837: Plasma Concentration of AZD0837 at End of Treatment</title>
          <population>Only patients who switched to one dose, 300 mg od, are included in the AZD0837 analysis</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="675" lower_limit="10" upper_limit="4090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AR-H067637XX, the Active Major Metabolite of AD0837: Plasma Concentration of AR-H067637XX, at End of Treatment</title>
        <time_frame>154-711 days on treatment</time_frame>
        <population>Only patients who switched to one dose, 300 mg od, are included in the AZD0837 analysis</population>
        <group_list>
          <group group_id="O1">
            <title>AZD0837</title>
            <description>Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od, then switching to one general common dose, 300 mg od.</description>
          </group>
        </group_list>
        <measure>
          <title>AR-H067637XX, the Active Major Metabolite of AD0837: Plasma Concentration of AR-H067637XX, at End of Treatment</title>
          <population>Only patients who switched to one dose, 300 mg od, are included in the AZD0837 analysis</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341" lower_limit="10" upper_limit="929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>154-711 days on treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AZD0837</title>
          <description>Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od</description>
        </group>
        <group group_id="E2">
          <title>VKA INR 2-3</title>
          <description>Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Chordae Tendinae Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Heart Valve Incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Eye Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Retinal Artery Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Anal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Anal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Periodontal Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Jaundice Cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal Graft Rejection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Intervertebral Discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Foreign Body Trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>International Normalised Ratio Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Inguinal Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Muscle Atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Scleroderma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Colon Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Colon Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Metastases To Central Nervous System</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cerebral Artery Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Status Epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Vascular Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delusional Disorder, Persecutory Type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dysthymic Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Urinary Bladder Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Postmenopausal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Arterial Stenosis Limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Peripheral Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Subclavian Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>800003Varicose Vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

